Drug intelligence / Profile preview

AQR-924

Development stage: Preclinical
Lead developer: Aquavit Pharmaceuticals
Administration: Intradermal

Overview

AQR-924 (AQUABELO) is a medical device developed by Aquavit Pharmaceuticals consisting of freeze-dried hyaluronic acid. It is designed for dermal augmentation, providing structural support and volume to the skin through injection. Unlike traditional liquid or gel fillers, its freeze-dried formulation is intended to offer unique stability or reconstitution properties for aesthetic and therapeutic correction of skin volume loss. The product is currently listed in the developer's pipeline for dermal augmentation, though specific clinical phase details and regulatory approval status are not extensively documented in public clinical trial registries.

Brand names: AQUABELO
Other names: freeze-dried hyaluronic acid

Beyond the preview

Go deeper on AQR-924.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AQR-924.

Explore the full profile